Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.